Updated Jul 16, 2026
ORBIMED ADVISORS LLC has filed 12 SEC Form 4 filings across 6 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $63.00M. Lifetime open-market sales: $154.99M. Historical track record: 4/5 stars across 8 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★☆ (4/5) |
|---|---|
| Total purchases tracked | 8 |
| Purchases with forward-return data | 8 |
| 30-day win rate | 7500% |
| 90-day win rate | 2500% |
| Avg 5-day return | +107.68% |
| Avg 30-day return | +3498.49% |
| Avg 90-day return | +174.49% |
| Best 30-day return | +13648.99% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-09 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 85.9K | $44.86 | $3.85M |
| 2026-07-02 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 115.8K | $45.50 | $5.27M |
| 2026-06-24 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 46.8K | $45.00 | $2.10M |
| 2026-06-24 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 787.0K | $45.38 | $35.72M |
| 2026-06-24 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.5K | $45.00 | $66K |
| 2026-06-24 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 24.8K | $45.38 | $1.13M |
| 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 272.3K | $45.02 | $12.26M |
| 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 9.1K | $45.02 | $409K |
| 2026-06-02 | QTTB | Q32 Bio Inc. | P — Open-market purchase | 625.0K | $8.00 | $5.00M |
| 2026-06-02 | QTTB | Q32 Bio Inc. | P — Open-market purchase | 1.25M | $8.00 | $10.00M |
| 2026-05-30 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 101 | $44.49 | $4K |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 184.6K | $46.22 | $8.53M |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 59.8K | $44.58 | $2.66M |
| 2026-05-11 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 48.5K | $44.61 | $2.17M |
| 2026-04-29 | TRAW | Traws Pharma, Inc. | P — Open-market purchase | 597.7K | $1.67 | $998K |
| 2026-04-23 | PRLD | Prelude Therapeutics Inc | P — Open-market purchase | 1.13M | $4.44 | $5.00M |
| 2026-04-23 | PRLD | Prelude Therapeutics Inc | P — Open-market purchase | 1.69M | $4.44 | $7.50M |
| 2026-04-22 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 2.9K | $44.52 | $131K |
| 2026-04-22 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 52.4K | $44.68 | $2.34M |
| 2026-04-16 | SION | Sionna Therapeutics, Inc. | S — Open-market sale | 226.9K | $45.34 | $10.29M |
ORBIMED ADVISORS LLC is a corporate insider — currently tracked as Director of Sionna Therapeutics, Inc. (SION). InsiderAlpha tracks every SEC Form 4 filing in real time.
12 primary Form 4 filings in the last 90 days, covering 6 companies.
Recorded transactions: 24 open-market purchases ($63.00M) and 53 open-market sales ($154.99M) across all tracked filings.
Across 8 tracked purchases, ORBIMED ADVISORS LLC averaged +3498.5% avg 30-day return with a 7500% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live ORBIMED ADVISORS LLC profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.